Jazz Pharmaceuticals PLC (JAZZ) SVP Paul Treacy Sells 1,309 Shares of Stock
Jazz Pharmaceuticals PLC (NASDAQ:JAZZ) SVP Paul Treacy sold 1,309 shares of the business’s stock in a transaction on Friday, August 10th. The shares were sold at an average price of $176.61, for a total transaction of $231,182.49. The transaction was disclosed in a legal filing with the SEC, which is accessible through this link.
Shares of NASDAQ:JAZZ opened at $175.37 on Tuesday. The firm has a market capitalization of $10.64 billion, a P/E ratio of 15.65, a price-to-earnings-growth ratio of 0.96 and a beta of 0.90. Jazz Pharmaceuticals PLC has a 1 year low of $128.58 and a 1 year high of $184.00. The company has a debt-to-equity ratio of 0.54, a current ratio of 3.76 and a quick ratio of 3.62.
Jazz Pharmaceuticals (NASDAQ:JAZZ) last issued its quarterly earnings data on Tuesday, August 7th. The specialty pharmaceutical company reported $3.49 earnings per share (EPS) for the quarter, topping the Zacks’ consensus estimate of $3.23 by $0.26. The firm had revenue of $500.48 million during the quarter, compared to analysts’ expectations of $469.85 million. Jazz Pharmaceuticals had a net margin of 24.20% and a return on equity of 25.47%. equities analysts anticipate that Jazz Pharmaceuticals PLC will post 11.64 EPS for the current year.
A number of large investors have recently modified their holdings of JAZZ. BlackRock Inc. lifted its position in Jazz Pharmaceuticals by 64.0% during the 2nd quarter. BlackRock Inc. now owns 4,372,080 shares of the specialty pharmaceutical company’s stock worth $753,311,000 after acquiring an additional 1,706,417 shares during the last quarter. FMR LLC lifted its position in Jazz Pharmaceuticals by 12.1% during the 2nd quarter. FMR LLC now owns 6,634,958 shares of the specialty pharmaceutical company’s stock worth $1,143,203,000 after acquiring an additional 715,595 shares during the last quarter. Congress Asset Management Co. MA acquired a new position in Jazz Pharmaceuticals during the 2nd quarter worth $87,276,000. AGF Investments Inc. acquired a new position in Jazz Pharmaceuticals during the 2nd quarter worth $78,345,000. Finally, Fiera Capital Corp acquired a new position in Jazz Pharmaceuticals during the 2nd quarter worth $54,662,000. Hedge funds and other institutional investors own 90.44% of the company’s stock.
About Jazz Pharmaceuticals
Jazz Pharmaceuticals plc, a biopharmaceutical company, identifies, develops, and commercializes pharmaceutical products for various medical needs in the United States, Europe, and internationally. The company has a portfolio of products and product candidates with a focus in the areas of sleep and hematology/oncology.
Recommended Story: Understanding Price to Earnings Ratio (PE)
Receive News & Ratings for Jazz Pharmaceuticals Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Jazz Pharmaceuticals and related companies with MarketBeat.com's FREE daily email newsletter.